Tenax Therapeutics Inc (TENX)

[skyticket1]

LEVO-CTS 408 patients enrolled as of Feb 8,2016 - 20 patients in 8 days enrolled and enrollment speed accelerating! With the assumption that 60 per month will be enrolled, phase 3 LEVO-CTS study, with FDA fast track approval, will be finished at the end of September 2016, with a potential data read out in Q1, 2017 and immediate approval. Probability of approval by the FDA is very very high, as this drug is accepted in over 50 countries world wide already !

buckle up shorties , here comes the ride !